sur Andera Partners
Andera Partners and Bpifrance Lead €27 Million Series B for EG 427
In a strategic move, Andera Partners and Bpifrance have co-led a €27 million Series B funding round for EG 427. This injection of capital aims to finance the ongoing phase 1b/2a clinical study of EG110A and further develop the company's proprietary HERMES vector technology platform. Specialist fund SCI Ventures and existing investors also participated in this round.
The funding supports the evaluation of EG110A, which targets neurogenic detrusor overactivity in spinal cord injury patients. The initiative aims to address critical neuro-urology pathologies. This financing facilitates EG 427's broader genetic medicine pipeline, with potential advancements in neuro-urology treatments.
The development employs non-replicative HSV vectors, promising affordable production costs and potential repeated dosing advantages. This approach could revolutionize treatments for neurological diseases, positioning EG 427 at the forefront of genetic medicine innovations.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Andera Partners